Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jamil Asselah is active.

Publication


Featured researches published by Jamil Asselah.


Journal of Surgical Oncology | 2016

Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases.

Eve Simoneau; Reema Alanazi; Jumanah Y AlShenaifi; Nouran Molla; Murad Aljiffry; Ahmad Medkhali; L.N. Boucher; Jamil Asselah; Peter Metrakos; Mazen Hassanain

Treatment strategies for colorectal cancer liver metastasis (CRCLM) such as major hepatectomy and portal vein embolization (PVE) rely on liver regeneration. We aim to investigate the effect of neoadjuvant chemotherapy on liver regeneration occurring after PVE and after major hepatectomy.


Cell Reports | 2017

A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Paul Savage; Alexis Blanchet-Cohen; Timothée Revil; Dunarel Badescu; Sadiq M. Saleh; Yu-Chang Wang; Dongmei Zuo; Leah Liu; Nicholas Bertos; Valentina Muñoz-Ramos; Mark Basik; Kevin Petrecca; Jamil Asselah; Sarkis Meterissian; Marie-Christine Guiot; Atilla Omeroglu; Claudia L. Kleinman; Morag Park; Jiannis Ragoussis

Therapies targeting epidermal growth factor receptor (EGFR) have variable and unpredictable responses in breast cancer. Screening triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), we identify a subset responsive to EGFR inhibition by gefitinib, which displays heterogeneous expression of wild-type EGFR. Deep single-cell RNA sequencing of 3,500 cells from an exceptional responder identified subpopulations displaying distinct biological features, where elevated EGFR expression was significantly enriched in a mesenchymal/stem-like cellular cluster. Sorted EGFRhi subpopulations exhibited enhanced stem-like features, including ALDH activity, sphere-forming efficiency, and tumorigenic and metastatic potential. EGFRhi cells gave rise to EGFRhi and EGFRlo cells in primary and metastatic tumors, demonstrating an EGFR-dependent expansion and hierarchical state transition. Similar tumorigenic EGFRhi subpopulations were identified in independent PDXs, where heterogeneous EGFR expression correlated with gefitinib sensitivity. This provides new understanding for an EGFR-dependent hierarchy in TNBC and for patient stratification for therapeutic intervention.


British Journal of Cancer | 2017

The use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer

Victoria Mandilaras; Nathaniel Bouganim; Hui Yin; Jamil Asselah; Laurent Azoulay

Background:Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensives. Recently, these drugs have been associated with a protective effect against pancreatic cancer, but data on this putative association remain limited. Thus, the objective of this study was to determine whether the use of ACEIs and/or ARBs is associated with a decreased risk of pancreatic cancer.Methods:We conducted a population-based cohort study, using a nested case–control analysis within the UK Clinical Practice Research Datalink population. The cohort consisted of all patients newly treated with antihypertensive drugs between 1 January 1995 and 31 December 2009, with follow-up until 31 December 2010. Cases were patients with newly diagnosed pancreatic cancer, which were matched with up to 10 controls on age, sex, calendar year of cohort entry, and duration of follow-up. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of pancreatic cancer incidence associated with ever use of ACEIs and ARBs. A secondary analysis was conducted to assess whether the incidence of pancreatic cancer varied with cumulative duration of use of these drugs.Results:A cohort of 547 566 was assembled. During 3 040 332 person-years of follow-up, a total of 866 patients were newly diagnosed with pancreatic cancer (rate: 3/10 000 per year) and matched to 8636 controls. Overall, when compared with other antihypertensive drugs, the use of ACEIs was not associated with a decreased risk of pancreatic cancer overall (OR: 1.01, 95% CI: 0.86–1.17) or according to cumulative duration of use. The use of ARBs was not associated with a decreased risk of pancreatic cancer overall (OR: 0.93, 95% CI: 0.75–1.15), whereas a cumulative duration of use of 1–3 years was associated with a 38% decrease (OR: 0.62, 95% CI: 0.41–0.94), which returned to the null after >3 years of use (OR: 1.04, 95% CI: 0.74–1.46).Conclusions:The use of ARBs and ACEIs was not associated with an overall decreased risk of pancreatic cancer when compared with patients using other antihypertensive drugs. Additional research is needed to determine whether ARBs may confer a short-term protective effect.


JCO Precision Oncology | 2018

Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries

Alyssa L. Smith; Cavin Wong; Adeline Cuggia; Ayelet Borgida; Spring Holter; Anita Hall; Ashton Connor; Claire Bascuñana; Jamil Asselah; Nathaniel Bouganim; Véronique Poulin; Jacques Jolivet; Petro Vafiadis; Philippe Le; Guillaume Martel; Frédéric Lemay; Annie Beaudoin; Khashayar Rafatzand; Prosanto Chaudhury; Jeffrey Barkun; Peter Metrakos; Victoria Marcus; Atilla Omeroglu; George Chong; Mohammad Akbari; William D. Foulkes; Steven Gallinger; George Zogopoulos

PurposeWe investigated the translational value of reflex testing for germline mutations in four homology-directed DNA repair predisposition genes (BRCA1, BRCA2, PALB2, and ATM) in consecutive patients with pancreatic adenocarcinoma.MethodsOne hundred fifty patients with French-Canadian (FC) ancestry were evaluated for founder mutations, and 114 patients were subsequently assessed by full gene sequencing and multiplex ligation-dependent probe amplification for nonfounder mutations. Two hundred thirty-six patients unselected for ancestry were also assessed for mutations by full gene sequencing.ResultsThe FC founder mutation prevalence among the 150 patients was 5.3% (95% CI, 2.6% to 10.3%), and the nonfounder mutation prevalence across the four genes among the 114 patients tested was 2.6% (95% CI, 0.6% to 7.8%). In the case series unselected for ancestry, 10.0% (95% CI, 2.7% to 26.4%) of patients reporting Ashkenazi Jewish (AJ) ancestry carried an AJ founder mutation, with no nonfounder mutations identified...


Journal of Gastrointestinal Surgery | 2014

Clinical Significance of Incidental Pulmonary Nodules in Esophageal Cancer Patients

Amin Madani; Jonathan Spicer; Thierry Alcindor; Marc David; Marie Vanhuyse; Jamil Asselah; David S. Mulder; Lorenzo E. Ferri


Journal of Clinical Oncology | 2017

Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

Jill Lacy; Fabienne Portales; Pascal Hammel; Roberto A. Pazo Cid; José Luis Manzano Mozo; Edward J. Kim; Scot Dowden; Christophe Borg; Javier Sastre; Venu Gopal Bathini; Eric Terrebonne; Daniel Lopez-Trabada; Fernando Rivera; Jamil Asselah; Azzurra Damiani; Jimmy J. Hwang; Teng Jin Ong; Thom Nydam; Jack Shiansong Li; Philip A. Philip


Journal of Clinical Oncology | 2017

Multi-institutional comparison of breast cancer risk stratification by 70-gene signature and 21-gene assay.

David J. Dabbs; Charles E. Cox; Steven C. Shivers; Nathaniel Bouganim; Jamil Asselah; Ramy Saleh; Lisa Eileen Blumencranz; Alberto J. Montero; Benjamin C. Calhoun; Tina Treece; William Audeh


Cancer Research | 2018

Abstract 1044: Establishment and characterization of rare breast patient-derived xenograft models as a potential resource for personalized medicine

Hellen Kuasne; Paul Savage; Constanza Martinez Ramirez; Leah Liu; Valentina Muñoz-Ramos; Virginie Pilon; Anie Monast; Radia Johnson; Nicholas R. Bertos; Jamil Asselah; Nathaniel Bouganim; Kevin Petrecca; Sarkis Meterissian; Atilla Omeroglu; Mark Basik; Morag Park


Journal of Clinical Oncology | 2017

The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.

Victoria Mandilaras; Nathaniel Bouganim; Jamil Asselah; Hui Yin; Laurent Azoulay


Journal of Clinical Oncology | 2015

The long-term use of calcium channel blockers and the risk of breast cancer.

Sara Victoria Soldera; Nathaniel Bouganim; Jamil Asselah; Hui Yin; Ralph Maroun; Laurent Azoulay

Collaboration


Dive into the Jamil Asselah's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hui Yin

Jewish General Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ramy Saleh

McGill University Health Centre

View shared research outputs
Top Co-Authors

Avatar

Atilla Omeroglu

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Sarkis Meterissian

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Kevin Petrecca

Montreal Neurological Institute and Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge